All News

Featured panelists at ExL’s annual Digital Pharma East conference this week included practicing physicians, vocal ePatients, social media gurus and digital marketing consultants with plenty of hours logged in big pharma boardrooms.

FDA’s head of neurology products told industry execs at the Prix Galien Forum that the agency is open to alternative clinical trial designs in Alzheimer’s disease, and would like to see more combination products in clinical testing.

In a New York Times op-ed this week, a trio of physicians from the Memorial Sloan Kettering Cancer Center in New York announced their decision to remove an expensive new cancer treatment from the hospital formulary, citing cost-benefit as their reason.

New stories earlier this year (1) reported that FDA scientists have been suspected of leaking confidential, commercial, and trade secret information to the media.

With Halloween candy flooding the shelves in pharmacies across the nation, it’s only appropriate that we turn the conversation toward an ever-growing drug market and therapeutic area: diabetes.

Lundbeck's Big Bet

S

Developing a drug is still very much a game of chance: a round puzzle of soft edges, with pieces that rarely fit the hard rectangles of time and money. Solving the puzzle correctly-with a new product as the sum of its parts-depends on making that lengthy progression from basic science to registration as linear as possible.

PE Ad Dimensions

PE June 2012 BPA

Even though Congress authorized both existing and new user fees for the Food and Drug Administration several months ago through the FDA Safety & Innovation Act (FDASIA).

The furore that burst across Brussels in late September over reported findings of tumors in rats fed with genetically modified maize may seem only tangentially related to the concerns.

The sessions focused heavily on the state of doing business in Brazil.

A recent decision by the Department of Health (DoH) to introduce a compliance regime for NICE (National Institute for Health and Clinical Excellence) technology.

Pharm Exec’s 2012 Industry Audit relies on 2011 data to compare performance against 2010.

Cegedim Relationship Management held its annual conference on trends in the life sciences industry last week.

CPhI Worldwide is the world's leading pharmaceutical networking event for Pharma Ingredients. Along with co-located events ICSE for Contract Services, InnoPack for Innovative Packaging and P-MEC Europe for Technology, Equipment and Machinery, this is a one-stop shop event that cannot be missed by anyone serving the (Bio)Pharmaceutical industry.

Innovation Excellence is a unique application of lean kaizen methodologies and personal coaching. It frees up capacity for innovative research, fosters ownership and significantly enhances the output of your research and innovation teams.

The Access to Medicines Index is an attempt to measure and compare the corporate social responsibility of both innovator (20) and generics (7) companies based on a number of different (and often quixotic) indicators.

The pharmaceutical industry still lags other industries in spending on outbound social media programs that engage customers directly.

The FDA and the Advanced Medical Technology Association (AdvaMed) gave cardiovascular device manufacturers plenty to think about over the holiday weekend with information presented at an Aug. 28 workshop.

Busting the Tape

Autumn is a good time to present our annual post on how well the industry is doing in harvesting value for shareholders. Our diverse list of 24 companies, drawn from Big Pharma to the established biotechs, presents a similarly mixed picture on returns: smaller firms with a distinct customer base and tight oversight of costs are by and large proving more adept at delivering the strong growth that investors still expect from this business.

"Payers have evolved to become powerful global contenders with pharma for increasingly limited funding of drug budgets."

It’s something of an enigma that most physicians are keen to learn about and use cutting edge medicines and devices for their patients.

In the American version of the Australian TV series Wilfred, the show’s title character declares that for him, human life begins at 10 years old.

Public policy activities should be a distinct, mission critical function for Big Pharma - our business depends increasingly on government as a key customer.

The European Union is at last groping its way towards some form of standardization in judging the value of medicines.

The European Union is at last groping its way towards some form of standardization in judging the value of medicines.